Cancer drug aims to mop up remaining leukemia cells after chemo

NCT ID NCT01258933

Terminated Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested the drug ofatumumab (Arzerra) in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who still had signs of disease after chemotherapy. The goal was to see if the drug could clear remaining cancer cells and keep the disease under control. Only 4 people took part, and the trial was stopped early, so the findings are very limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ofatumumab (Arzerra)
What this could lead to: If successful, this could show that ofatumumab helps clear remaining cancer cells after chemotherapy, potentially delaying relapse in CLL or SLL patients.
What could go wrong: This was a very small, early-phase trial that was terminated early, so results are limited. The drug may not work for everyone and can cause side effects like infusion reactions or infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia leukemia lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEUKEMIA LYMPHOMA

Contacts and locations

Locations

University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.